Expand into Europe: unlocking the orphan drug market
The European orphan drug market is growing rapidly, offering U.S. biotech companies a significant opportunity to expand into Europe. However, navigating the region’s complex regulatory, pricing, and reimbursement landscapes requires a strategic approach.
In this exclusive guide, we cover:
- Key regulatory pathways and market entry considerations for orphan drugs in Europe
- How to leverage early access programs and real-world data for market adoption
- The benefits of partnering with European specialists to streamline distribution and compliance
- Best practices for patient engagement, advocacy, and long-term market success
Download this guide to learn how to successfully commercialize your orphan drug and expand into Europe, ensuring both patient impact and commercial viability.
About Sciensus
Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.
Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.
